World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
125
Citations
75807
World Ranking
3034
National Ranking
1673

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Naga Chalasani is affiliated with Indiana University in the United States and specializes in medicine with a focus on hepatology and epidemiology. Their research areas encompass liver disease diagnosis and treatment, liver disease and transplantation, drug-induced hepatotoxicity and protection, as well as associated topics such as alcohol consumption and health effects, liver diseases and immunity, diet, metabolism, and disease, and hepatocellular carcinoma treatment and prognosis.

The scientist has authored numerous publications in prominent journals with frequent appearances in the Journal of Hepatology, Gastroenterology, Hepatology Communications, Hepatology, and The American Journal of Gastroenterology. These venues include 29, 28, 17, 16, and 16 publications respectively.

Among notable research papers authored or co-authored by Naga Chalasani are:

  • Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease, 2021, New England Journal of Medicine
  • Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial, 2021, Hepatology
  • ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury, 2021, The American Journal of Gastroenterology
  • High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population, 2021, Hepatology
  • A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation, 2022, Nature Genetics

Their frequent co-authors include Marwan Ghabril, Samer Gawrieh, Eric S. Orman, Raj Vuppalanchi, and Archita P. Desai, each having collaborated extensively in over 50 publications with Chalasani.

Chalasani's research deeply engages with subfields such as epidemiology, hepatology, pharmacology, surgery, and pathology and forensic medicine. The range of topics addressed highlights a strong orientation towards clinical and translational aspects of liver diseases and drug-induced liver injury.

The scientist has been recognized as a member of the Association of American Physicians, reflecting a professional affiliation within the medical community.

Best Publications

  • The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Michael Charlton

  • The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Anna Mae Diehl

  • Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

    Arun J. Sanyal;Naga Chalasani;Kris V. Kowdley;Arthur McCullough

  • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

    Brent A Neuschwander-Tetri;Rohit Loomba;Arun J Sanyal;Joel E Lavine

  • The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

    Naga Chalasani;Zobair Younossi;Joel E. Lavine;Anna Mae Diehl

  • Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial

    Joel E. Lavine;Jeffrey B. Schwimmer;Mark L. Van Natta;Jean P. Molleston;Jean P. Molleston

  • Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States

    Naga Chalasani;Robert J. Fontana;Herbert L. Bonkovsky;Herbert L. Bonkovsky;Herbert L. Bonkovsky;Paul B. Watkins

  • ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury

    Naga P. Chalasani;Paul Hideyo Hayashi;Herbert L. Bonkovsky;Victor J. Navarro

  • Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study

    Naga Chalasani;Herbert L. Bonkovsky;Robert Fontana;William Lee

  • Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

    Raj Vuppalanchi;Naga Chalasani

  • Endpoints and clinical trial design for nonalcoholic steatohepatitis.

    Arun J. Sanyal;Elizabeth M. Brunt;David E. Kleiner;Kris V. Kowdley

  • Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

    Eduardo Vilar-Gomez;Eduardo Vilar-Gomez;Luis Calzadilla-Bertot;Vincent Wai-Sun Wong;Marlen Castellanos

  • Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

    Arun J. Sanyal;Mark L. van Natta;Jeanne Clark;Brent A. Neuschwander-Tetri

  • Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

    Naga Chalasani;Hisham Aljadhey;Joe Kesterson;Michael D. Murray;Michael D. Murray

  • Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct

    Robert J. Fontana;Paul B. Watkins;Herbert L. Bonkovsky;Naga Chalasani

  • Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

    Kris V. Kowdley;Patricia Belt;Laura A. Wilson;Matthew M. Yeh

  • Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Eduardo Vilar-Gomez;Naga Chalasani

  • Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

    Brent A. Neuschwander-Tetri;Jeanne M. Clark;Nathan M. Bass;Mark L. Van Natta

  • Predictors of inadequate bowel preparation for colonoscopy.

    Reid M Ness;Raj Manam;Helena Hoen;Naga Chalasani

  • Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

    N. Chalasani;H. L. Bonkovsky;R. Fontana;W. Lee

Frequent Co-Authors

Robert J. Fontana
Robert J. Fontana University of Michigan–Ann Arbor
David E. Kleiner
David E. Kleiner National Institutes of Health
Arun J. Sanyal
Arun J. Sanyal Virginia Commonwealth University
Oscar W. Cummings
Oscar W. Cummings Indiana University
David W. Crabb
David W. Crabb Indiana University
Kris V. Kowdley
Kris V. Kowdley Washington State University
Paul B. Watkins
Paul B. Watkins University of North Carolina at Chapel Hill
Joel E. Lavine
Joel E. Lavine Columbia University
Rohit Loomba
Rohit Loomba University of California, San Diego
Jay H. Hoofnagle
Jay H. Hoofnagle National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a future in medicine opens several alternative degree and career pathways, especially with the flexibility of online learning. For students wanting to work on the administrative side of healthcare, an affordable healthcare administration degree online can be a smart, budget-friendly option. These programs provide foundational knowledge in management, policy, and operations within healthcare systems.

For those motivated to oversee healthcare facilities or lead within the sector, pursuing the cheapest online master degree in healthcare administration can help you reach advanced roles without breaking the bank.

If you are already a registered nurse aiming for the highest clinical positions, the cheapest dnp programs online offer a pathway to leadership and practice-based expertise.

Future pharmacists can also benefit from pharmacy school online accredited programs, allowing you to earn a respected doctorate degree while maintaining flexibility in your schedule.

These online degree options are not only accessible and cost-effective, but also open doors to a wide range of fulfilling healthcare careers beyond the traditional path to medical school.

Best Scientists Citing Naga Chalasani

Trending Scientists

Recently Published Articles